JPH01313438A - Anti-periodontosis composition - Google Patents
Anti-periodontosis compositionInfo
- Publication number
- JPH01313438A JPH01313438A JP63145489A JP14548988A JPH01313438A JP H01313438 A JPH01313438 A JP H01313438A JP 63145489 A JP63145489 A JP 63145489A JP 14548988 A JP14548988 A JP 14548988A JP H01313438 A JPH01313438 A JP H01313438A
- Authority
- JP
- Japan
- Prior art keywords
- periodontosis
- antibody
- composition
- egg
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 208000010266 Aggressive Periodontitis Diseases 0.000 title abstract 8
- 201000006727 periodontosis Diseases 0.000 title abstract 8
- 241000894006 Bacteria Species 0.000 claims abstract description 26
- 208000028169 periodontal disease Diseases 0.000 claims description 24
- 210000000991 chicken egg Anatomy 0.000 claims description 16
- 235000013601 eggs Nutrition 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 7
- 210000000214 mouth Anatomy 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 235000013345 egg yolk Nutrition 0.000 abstract description 5
- 102000002322 Egg Proteins Human genes 0.000 abstract description 4
- 108010000912 Egg Proteins Proteins 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000000427 antigen Substances 0.000 abstract description 3
- 102000036639 antigens Human genes 0.000 abstract description 3
- 108091007433 antigens Proteins 0.000 abstract description 3
- 210000002969 egg yolk Anatomy 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002324 mouth wash Substances 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000000551 dentifrice Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 229940051866 mouthwash Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000605862 Porphyromonas gingivalis Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000018035 Dental disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000014151 Stomatognathic disease Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000902235 Oides Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-N fluorophosphoric acid Chemical compound OP(O)(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyphenol compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は歯周病の予防に有効な組成物に関する。きらに
詳述すれば、バタテロイデス・ジンジバリス（Ｂａｃｔ
ｅｒｏｉｄｅｓ ｇｉｎｇｉｖａｌｉｓ）等の歯周病
原因菌の口腔内の定着および増殖を抑制し、歯周病疾患
を予防することができる抗歯同病組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a composition effective in preventing periodontal disease. To be more specific, Bacteroides gingivalis (Bact.
The present invention relates to an anti-odontopathy composition capable of inhibiting the colonization and proliferation of periodontal disease-causing bacteria such as (Eroides gingivalis) in the oral cavity and preventing periodontal diseases.
成人の歯周疾患に罹患する率は年々増加しており、今後
高齢化社会に移行するなかで歯周疾患の予防は重要な問
題である。しかし、歯周病の病原菌に関して科学的に確
たる手がかりが得られたのはごく最近のことである。現
時点で歯周病と病因論的因果関係が深いと考えられる菌
として、バクテロイデスφジンジバリス（Ｂａｃｔｅｒ
ｏｉｄｅｓ ｇｉｎｇｉｖａｌｉｓ）、アクチノバチ
ルス・アクチノマイセテムコミタンス（Ａｃｔｉｎｏｂ
ａｃｉｌｌｕｓ ａｃｔｉｎｏｍｙｃｅｔｅｍｃｏｍ
ｉｔａｎｓ）、フッバクテリウム・ヌクレエイタム（Ｆ
ｕｓｏｂａｃｔｅｒｉｕｍ ｎｕｃｌｅａｔｕｍ）お
よびバタテロイデス・メラニノゲニクス・サブスピーシ
ーズ・メラニノゲニクス（Ｂａｃｔｅｒｏｉｄｅｓ
ｍｅｌａｎｉｎ。The incidence of periodontal disease in adults is increasing year by year, and prevention of periodontal disease is an important issue as we move into an aging society. However, it is only recently that solid scientific clues about the pathogens of periodontal disease have been obtained. At present, Bacteroides gingivalis is considered to have a deep etiological relationship with periodontal disease.
oides gingivalis), Actinobacillus actinomycetemcomitans (Actinobacillus gingivalis)
acillus actinomycetem com
itans), Hubbacterium nucleatum (F
usobacterium nucleatum) and Bacteroides melaninogenus subsp.
melanin.
ｇｅｎｉｃｕｓ ５ｕｂｓｐ、 ｍｅｌａｎｉｎｏ
ｇｅｎｉｃｕｓ）等があげられる。歯周疾患を予防する
には、これら原因菌の口腔内への定着を阻止し、増殖を
抑えることが考えられる。従来、この目的に主として抗
生物質あるいは、化学合成殺菌剤が用いられてきた。ま
た幾つかの植物抽出物の抗菌性を利用した口腔内組成物
に関する報告もある（持分 昭６２−５８３２６．特公
昭６２−５８３２７）。genicus 5ubsp, melanino
genicus), etc. In order to prevent periodontal disease, it is possible to prevent these causative bacteria from colonizing the oral cavity and suppress their proliferation. Conventionally, antibiotics or chemically synthesized fungicides have been mainly used for this purpose. There are also reports on oral compositions that utilize the antibacterial properties of some plant extracts (Kiken No. 58326/1983; Special Publication No. 58327/1983).
従来の抗生物質や殺菌剤は長期連用に不適であり予防を
目的として使えない、また口腔内細菌を無差別に死滅さ
せ、常在菌叢の均衡を崩し一菌交代症等を引き起こし、
好ましからぬ状況をもたらすことが多い。Conventional antibiotics and bactericides are unsuitable for long-term use and cannot be used for preventive purposes, and they also kill oral bacteria indiscriminately, disrupting the balance of the normal flora and causing bacterial replacement.
This often results in undesirable situations.
他方、すでに既報告の有効植物抽出液は、その原料植物
の大量入手が困難であり、かつ高価であり、しかも抽出
物の添加により風味が損なわれる等問題が多い。On the other hand, effective plant extracts that have already been reported have many problems, such as difficulty in obtaining large amounts of raw material plants, high prices, and flavor loss due to the addition of extracts.
上記現状から、歯周疾患の原因菌に対して特異的に抗−
作用を示し、かつ予防を目的とした長期の連用に於て安
全性が高く、しかも安価に大量製造が可能な抗歯同病組
成物の開発が望まれている〔問題を解決するための手段
〕
本発明者らは、歯周疾患の原因菌に、対して高い抗菌作
用を示し、かつ予防を目的とした長期の連用に於て安全
性の高い物質を探すへく鋭意研究をを重ねた結果、歯周
病原因菌に特異的に結合する鶏卵抗体が同菌の生育を阻
害することを見い出し、該鶏卵抗体の応用として本発明
を完成させた。Based on the above-mentioned current situation, it has been found that
There is a desire for the development of an anti-dental disease composition that is effective, highly safe for long-term use for preventive purposes, and that can be mass-produced at low cost [Means for solving the problem] ] The present inventors have conducted extensive research in search of a substance that has a high antibacterial effect against the bacteria that causes periodontal disease and is highly safe when used over a long period of time for the purpose of prevention. As a result, the inventors discovered that a chicken egg antibody that specifically binds to periodontal disease-causing bacteria inhibits the growth of the bacteria, and completed the present invention as an application of the chicken egg antibody.
すなわち本発明は、歯周病の原因菌に特異的に結合子る
鶏卵抗体を含有する抗歯同病組成物に関する。That is, the present invention relates to an anti-periodontal disease composition containing a chicken egg antibody that specifically binds to periodontal disease-causing bacteria.
本発明の歯周病原因菌とは、一般的に歯周病と病因論的
因果関係が深いと考えられている、バクテロイデス・ジ
ンジバリス、アクチノバチルス・アクチノマイセテムコ
ミタンス、フンバクテリウム・ヌクレエイタム、および
バクテロイデス・メラニノゲニクス・サブスピーシーズ
・メラニノゲニクス等をいう。The periodontal disease-causing bacteria of the present invention include Bacteroides gingivalis, Actinobacillus actinomycetemcomitans, Humbacterium nucleatum, which are generally considered to have a deep etiological relationship with periodontal disease. and Bacteroides melaninogenus subspecies melaninogenus, etc.
これら歯周病原因菌に特異的に結合する鶏卵抗体は、該
菌を抗原として過免疫しためん鶏の産する卵の卵黄より
得られる。この鶏卵抗体の工業的精製方法は、本発明者
らが先に出願した特許（特許出願番号 昭和６２年−１
９４０８３号）に詳細に例示されるが、他の方法に依っ
てもさしつかえない。Chicken egg antibodies that specifically bind to these periodontal disease-causing bacteria are obtained from the yolks of eggs produced by hens that have been hyperimmunized with the bacteria as antigens. This industrial purification method for egg antibodies is based on a patent previously filed by the present inventors (patent application number 1988-1).
No. 94083), but other methods may also be used.
また、歯周病原因菌に特異的に結合する抗体は、ウサギ
、ヤギ、ヒツジ、等の哺乳動物を該菌で過免疫すること
で該動物の血液からも得られる。Antibodies that specifically bind to periodontal disease-causing bacteria can also be obtained from the blood of mammals such as rabbits, goats, and sheep by hyperimmunizing them with the bacteria.
しかしながら、この様にして得た抗体は、動物血液から
得られた抗体ということで使用者に与えるイメージが悪
い。また、特異的抗体の生産において、哺乳動物を用い
てその血液から得る方法は。However, the antibodies obtained in this way give a bad impression to users because they are antibodies obtained from animal blood. Also, in the production of specific antibodies, there is a method for obtaining them from the blood of mammals.
鶏を用いてその鶏卵卵黄から得る方法に比較し。Compared to the method obtained from chicken egg yolk using chickens.
抗体収量が劣るため大量生産には適さない。さらには、
血液抗体は補体の活性化作用を有し、好中球を刺激する
ため、局所的炎症反応が過大に起こる可能性がある。従
って、抗歯同病組成物として哺乳類血液抗体を用いるこ
とは好ましくない。Not suitable for mass production due to poor antibody yield. Furthermore,
Blood antibodies have a complement activation effect and stimulate neutrophils, which may lead to an exaggerated local inflammatory response. Therefore, it is not preferable to use mammalian blood antibodies as an anti-odontopathy composition.
本発明における鶏卵抗体は、容易にかつ大量に調製する
ことが可能である。しかも、補体の活性化作用を持たず
、局所的炎症反応の心配もないという利点を有する。The chicken egg antibody in the present invention can be easily prepared in large quantities. Moreover, it has the advantage that it does not have a complement activation effect and there is no need to worry about local inflammatory reactions.
本発明に用いられる鶏卵抗体の抗歯同病組成物への配合
量は、その抗体価により大幅に異なるため、抗体価の測
定を行い適時決定することが望ましい。一般的には、常
法で過免疫された鶏の鶏卵抗体を用いた場合０．００１
％（重量部）以上である。Since the amount of the egg antibody used in the present invention to be incorporated into the anti-dentitis composition varies greatly depending on the antibody titer, it is desirable to determine the amount in a timely manner by measuring the antibody titer. In general, when using egg antibodies from chickens that have been hyperimmunized using a conventional method, 0.001
% (parts by weight) or more.
本発明の抗歯同病組成物の剤形は、洗口液、うがい薬、
塗布液剤、歯みがき剤、トローチ剤、チューインガム等
その使用法に合わせて適宜選択できる。The dosage form of the anti-dentitis composition of the present invention includes mouthwash, gargle,
A coating solution, a toothpaste, a troche, a chewing gum, etc. can be selected as appropriate depending on the method of use.
本発明の抗歯同病組成物には、ポリフェノール化合物等
の抗菌剤、デキストラナーゼ等の酵素・剤、増粘剤、ｐ
Ｈ・調整剤２香料２色素、アルコール、水等の補助成分
を本発明の効果を損なわない範囲で適宜配合することが
できる。The anti-dentitis composition of the present invention includes antibacterial agents such as polyphenol compounds, enzymes and agents such as dextranase, thickeners,
Auxiliary components such as H.Adjuster 2Fragrance 2Pigment, alcohol, water, etc. can be blended as appropriate within a range that does not impair the effects of the present invention.
本発明における鶏卵抗体は口腔内において、歯肉内部に
浸透し、常在する歯周病原因菌表面に特異的に結合する
ことにより、その増殖を抑制するものと考えられる。It is thought that the egg antibody of the present invention infiltrates the inside of the gums in the oral cavity and specifically binds to the surface of resident periodontal disease-causing bacteria, thereby suppressing the proliferation thereof.
鶏卵抗体は、昔から人類に食されてきた鶏卵の−成分で
あり、その体内摂取においても人体に対する安全性は確
認されている。Chicken egg antibodies are components of chicken eggs that have been eaten by humans since ancient times, and their safety for human bodies has been confirmed when ingested.
以下に試験例および実施例を示し、本発明をより詳細に
説明する。The present invention will be explained in more detail by showing test examples and examples below.
試験例
ＣＡＭブイヨン培地（日水製薬株式会社製）でバクテロ
イデス・ジンジバリスＧＡＩ７８０２を培養後、同菌を
０．５％ホルマリンで常法に従い不活化し、ワクチンと
した。Test Example After culturing Bacteroides gingivalis GAI7802 in CAM broth medium (manufactured by Nissui Pharmaceutical Co., Ltd.), the bacterium was inactivated with 0.5% formalin according to a conventional method to prepare a vaccine.
産卵鶏をこの不活化ワクチン（ＩＸＩ Ｏ°菌数／ｍり
で過免疫（１ｍｊ２．筋肉注射×４回）し、その鶏卵卵
黄より抗体を精製した。具体的には卵黄１容量と１ｍｇ
／ｍｌ１度のλ−カラギーナン水溶液５容量を混合し、
生じるリポタンパク質の凝集物を遠心分離により除去し
た。こうして得られた上清液は約８０％の回収率で鶏卵
抗体を含む。この上清液より硫酸ナトリュウムを用いた
分画塩析法で鶏卵抗体の純品を得た。鶏卵抗体は１７％
（Ｗ／Ｖ）硫酸ナトリュウム濃度で塩析物として得られ
、他の不純物は遠心上清として除去される。こうして得
られた鶏卵抗体は、１０μｇで抗原として用いた上記歯
周病病原菌ｌＸｌ０”個を凝集する力価を示した。Laying hens were hyperimmunized (1 mj 2. intramuscular injection x 4 times) with this inactivated vaccine (IXI O° bacterial count/m), and antibodies were purified from the chicken egg yolks.Specifically, 1 volume of egg yolk and 1 mg
/ml 1 degree λ-carrageenan aqueous solution was mixed,
The resulting lipoprotein aggregates were removed by centrifugation. The supernatant thus obtained contains egg antibodies with a recovery rate of about 80%. A pure egg antibody was obtained from this supernatant by fractional salting out using sodium sulfate. Chicken egg antibodies are 17%
(W/V) sodium sulfate concentration as a salting out product, and other impurities are removed as a centrifugation supernatant. The chicken egg antibody thus obtained exhibited a titer of agglutinating 1X10'' of the above-mentioned periodontal disease pathogenic bacteria used as an antigen at 10 μg.
この鶏卵抗体をＣＡＭブイヨン培地へ１．１０．１０．
０１）Ｉ）ｍの濃度に添加し、それぞれの５ｍＰに対し
、バクテロイデス・ジンジノくリスＧＡＩ７８０２菌を
初発菌数１．ｏｘｔｏ’、、”ｍｘとなるよう加え、３
７℃で嫌気的に培養し、３日、６日、９日目の生菌数を
ＣＡＭ寒天培地で測定した。その結果を表１に示した。Add this chicken egg antibody to CAM broth medium 1.10.10.
01) I) m), and Bacteroides ginginocris GAI 7802 bacteria were added to each 5 mP to an initial number of 1. oxto',,”mx, 3
The cells were cultured anaerobically at 7°C, and the number of viable bacteria was measured on the CAM agar medium on the 3rd, 6th, and 9th day. The results are shown in Table 1.
尚、対照とし°ては鶏卵抗体を全く加えないものを同様
に操作した。As a control, the same procedure was performed without adding any chicken egg antibody.
表１に示す如く、対照と比較し、抗歯周病原囚菌鶏卵抗
体１０ｐｐｍ以上含むものは、同菌に対する抗菌作用を
示した。As shown in Table 1, compared to the control, those containing 10 ppm or more of anti-periodontal pathogenic bacteria egg antibodies showed antibacterial activity against the same bacteria.
実施例１．洗口液
粉末クエン酸 ０．１４４クエン酸ナトリ
ウム ０．１０２乳酸カルシウム ０
．０１２塩化マグネシウム ０．０１２粉末天
然香料 ０．１２０ビタミンＣ０，００１
８
本発明の鶏卵抗体 ０．０１
水 残量
全 量 １００．０（重量％）実施例２
．歯磨剤
第２リン酸カルシウム ４２．０
グリセリン １９．０
カラギーナン ０．９
ラウリル硫酸ナトリウム １．２
サツカリン １．０
本発明の鶏卵抗体 ０．０１
パラオキシ安息香酸ブチル ｏ、ｏｏｓ香料
１．０
水 残 量全 量
１００．０（重量％）実施例３．チューイン
ガム
ガムベース ２５．０
炭酸カルシウム ２．０
ソルビトール ５５．０
マンニトール １６．０
香料 １．０
本発明の鶏卵抗体 ０．０１
水 残量
全 量 １００．０（重量％）実施例４
．うがい用錠剤
羨酸水素ナトリウム ５４．０
第２リン酸ナトリウム １０．０
ポリエチレングリコール ３．０
香料 １．５
オレイン酸 ０．１
モノフルオロリン酸 ０．１
ナトリウム
クロルヘキシジン ０．０３
本発明の鶏卵抗体 ０．０１
アラントイン ０．１
クエン酸 １７．０
水 残量
全 量 １００．０（重量％）〔本発明
の効果〕
本発明の有効成分である抗歯同病原因菌特異的鶏卵抗体
は歯周病原因菌に特異的に結合し、生育を阻害する。従
って口腔内の他の常在細菌叢を乱すことはない。鶏卵抗
体は、人類が古くから食用に供している鶏卵卵黄の一成
分であり、その安全性は認められている。また近年、鶏
卵は安価である。Example 1. Mouth rinse powder citric acid 0.144 Sodium citrate 0.102 Calcium lactate 0
．． 012 Magnesium Chloride 0.012 Powder Natural Flavor 0.120 Vitamin C0,001
8 Egg antibody of the present invention 0.01 Water Total remaining amount 100.0 (wt%) Example 2
．． Dentifrice dibasic calcium phosphate 42.0 Glycerin 19.0 Carrageenan 0.9 Sodium lauryl sulfate 1.2 Satucalin 1.0 Egg antibody of the present invention 0.01 Butyl paraoxybenzoate o, oos fragrance
1.0 Total amount of water remaining
100.0 (wt%) Example 3. Chewing gum Gum base 25.0 Calcium carbonate 2.0 Sorbitol 55.0 Mannitol 16.0 Flavor 1.0 Egg antibody of the present invention 0.01 Water Total remaining amount 100.0 (wt%) Example 4
．． Gargle Tablet Sodium hydrogen envyate 54.0 Sodium dibasic phosphate 10.0 Polyethylene glycol 3.0 Flavor 1.5 Oleic acid 0.1 Monofluorophosphoric acid 0.1 Sodium chlorhexidine 0.03 Egg antibody of the present invention 0 .01 Allantoin 0.1 Citric acid 17.0 Water Total remaining amount 100.0 (wt%) [Effects of the present invention] The anti-dental disease-causing bacteria-specific chicken egg antibody, which is the active ingredient of the present invention, is effective against periodontal disease. It specifically binds to the causative bacteria and inhibits their growth. Therefore, it does not disturb other normal bacterial flora in the oral cavity. Chicken egg antibodies are a component of chicken egg yolk, which has been eaten by humans since ancient times, and its safety is recognized. Also, chicken eggs have become cheap in recent years.
従って、本発明の抗歯同病組成物は、安価にかつ大量に
供給することができる。また歯周疾患の予防を目的とし
て常用しても安全性に全く問題ない。このような効果を
有する本発明の歯周病組成物は、今後ますます増加する
と考えられる歯周疾患の予防に貢献することはもちろん
、産業的にも極めて有効であると考えられる。Therefore, the anti-dentitis composition of the present invention can be supplied inexpensively and in large quantities. Moreover, there is no problem with safety even if it is regularly used for the purpose of preventing periodontal diseases. The periodontal disease composition of the present invention having such effects not only contributes to the prevention of periodontal diseases, which are expected to increase further in the future, but is also considered to be extremely effective industrially.
Claims (1)
抗歯周病組成物。An anti-periodontal disease composition containing a chicken egg antibody that specifically binds to periodontal disease-causing bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63145489A JPH07116059B2 (en) | 1988-06-13 | 1988-06-13 | Anti-periodontal disease composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63145489A JPH07116059B2 (en) | 1988-06-13 | 1988-06-13 | Anti-periodontal disease composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01313438A true JPH01313438A (en) | 1989-12-18 |
| JPH07116059B2 JPH07116059B2 (en) | 1995-12-13 |
Family
ID=15386445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63145489A Expired - Fee Related JPH07116059B2 (en) | 1988-06-13 | 1988-06-13 | Anti-periodontal disease composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07116059B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0253458A (en) * | 1988-08-18 | 1990-02-22 | Lion Corp | Food |
| US5712102A (en) * | 1993-11-10 | 1998-01-27 | Bristol-Myers Squibb Company | Method of screening compounds which inhibit P. gingivalis lipopolysaccharide from inhibiting the extravasation of leukocytes |
| US5759544A (en) * | 1992-07-23 | 1998-06-02 | Lion Corporation | Antibody-containing oral composition for suppression of periodontal disease |
| US6160087A (en) * | 1993-09-28 | 2000-12-12 | Meito Sangyo Kabushiki Kaisha | Peptides having an amino acid sequence from the fimbrial protein of porphyromonas gingivalis and their uses |
| WO2006022409A1 (en) * | 2004-08-27 | 2006-03-02 | Daikin Industries, Ltd. | Hazardous substance scavenger and application apparatus and application method therefor |
| JP2011073997A (en) * | 2009-09-29 | 2011-04-14 | Nippon Zettoc Co Ltd | Composition for oral cavity |
| JP2011079779A (en) * | 2009-10-07 | 2011-04-21 | Dhc Co | Chewing material for dental care |
| WO2013047745A1 (en) * | 2011-09-30 | 2013-04-04 | 日本ゼトック株式会社 | Oral composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277632A (en) * | 1985-06-04 | 1986-12-08 | Lion Corp | Composition for oral cavity application |
| JPS62175462A (en) * | 1986-01-18 | 1987-08-01 | バイエル・アクチエンゲゼルシヤフト | Substituted-1,4-dihydropyridine-3-carboxylic acid piperazides |
| JPS62175426A (en) * | 1986-01-27 | 1987-08-01 | Kazufumi Shimizu | Antibody and spraying agent containing said substance as active component |
-
1988
- 1988-06-13 JP JP63145489A patent/JPH07116059B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277632A (en) * | 1985-06-04 | 1986-12-08 | Lion Corp | Composition for oral cavity application |
| JPS62175462A (en) * | 1986-01-18 | 1987-08-01 | バイエル・アクチエンゲゼルシヤフト | Substituted-1,4-dihydropyridine-3-carboxylic acid piperazides |
| JPS62175426A (en) * | 1986-01-27 | 1987-08-01 | Kazufumi Shimizu | Antibody and spraying agent containing said substance as active component |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0253458A (en) * | 1988-08-18 | 1990-02-22 | Lion Corp | Food |
| JP2689511B2 (en) * | 1988-08-18 | 1997-12-10 | ライオン株式会社 | Food |
| US5759544A (en) * | 1992-07-23 | 1998-06-02 | Lion Corporation | Antibody-containing oral composition for suppression of periodontal disease |
| US6160087A (en) * | 1993-09-28 | 2000-12-12 | Meito Sangyo Kabushiki Kaisha | Peptides having an amino acid sequence from the fimbrial protein of porphyromonas gingivalis and their uses |
| US5712102A (en) * | 1993-11-10 | 1998-01-27 | Bristol-Myers Squibb Company | Method of screening compounds which inhibit P. gingivalis lipopolysaccharide from inhibiting the extravasation of leukocytes |
| US5840302A (en) * | 1993-11-10 | 1998-11-24 | Bristol-Myers Squibb Company | Treatment of bacterially-induced inflammatory diseases |
| WO2006022409A1 (en) * | 2004-08-27 | 2006-03-02 | Daikin Industries, Ltd. | Hazardous substance scavenger and application apparatus and application method therefor |
| JP2011073997A (en) * | 2009-09-29 | 2011-04-14 | Nippon Zettoc Co Ltd | Composition for oral cavity |
| JP2011079779A (en) * | 2009-10-07 | 2011-04-21 | Dhc Co | Chewing material for dental care |
| WO2013047745A1 (en) * | 2011-09-30 | 2013-04-04 | 日本ゼトック株式会社 | Oral composition |
| JP2013075875A (en) * | 2011-09-30 | 2013-04-25 | Nippon Zettoc Co Ltd | Oral composition |
| US9724282B2 (en) | 2011-09-30 | 2017-08-08 | Nippon Zettoc Co., Ltd. | Stomatological composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07116059B2 (en) | 1995-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2167299A (en) | Dental caries-preventive composition | |
| US4689221A (en) | Oral composition containing antibodies to Bacteroides gingivalis | |
| CA1275380C (en) | Composition for oral application | |
| JPS6038329A (en) | Preventive for dental caries | |
| JPS5929619A (en) | Preventing agent for carious tooth | |
| JPH01313438A (en) | Anti-periodontosis composition | |
| WO2013047745A1 (en) | Oral composition | |
| US4911918A (en) | Oral composition containing stabilized antibody | |
| JP2001510803A (en) | Maternal immunosecretion and its use in the treatment and / or prevention of conditions in the human body | |
| JP5756615B2 (en) | Autoinducer-2 inhibitor and preventive and / or therapeutic agent for periodontal disease or caries disease | |
| JPH0253716A (en) | Composition for oral cavity application | |
| JP7445910B2 (en) | Oral compositions, oral care products, and foods containing oral resident bacteria regulators | |
| JP5881287B2 (en) | Autoinducer-2 inhibitor | |
| JP5756614B2 (en) | Autoinducer-2 inhibitor and preventive and / or therapeutic agent for caries disease | |
| JPH0421648B2 (en) | ||
| JPS62417A (en) | Composition for oral cavity application | |
| KR101144221B1 (en) | Composition for the management and improvement of oral health | |
| JPH045222A (en) | Crude drug extract for oral cavity and composition for oral cavity containing the same as active ingredient | |
| JP2007519622A (en) | Antibacterial composition | |
| JPH01265010A (en) | Cariostatic and antiperiodontic composition | |
| JPH0710728A (en) | Composition for oral cavity | |
| JPS61277632A (en) | Composition for oral cavity application | |
| JP5946608B2 (en) | Autoinducer-2 inhibitor | |
| JPH03115213A (en) | Caries preventing agent composition | |
| JPH01313439A (en) | Anti-acne vulgaris bacteria skin drug for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |